Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Short Interest Update

Share on StockTwits

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,740,000 shares, a growth of 13.7% from the January 15th total of 1,530,000 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 0.9 days.

In other news, Director James Noble sold 300,000 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $4.67, for a total value of $1,401,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Peter W. Sonsini acquired 7,500,000 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was acquired at an average cost of $0.67 per share, for a total transaction of $5,025,000.00. The disclosure for this purchase can be found here. Insiders sold a total of 317,323 shares of company stock worth $1,447,506 over the last three months. 22.36% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of ADAP. Tower Research Capital LLC TRC raised its stake in Adaptimmune Therapeutics by 21,372.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock worth $32,000 after buying an additional 21,372 shares during the period. Raymond James & Associates raised its stake in shares of Adaptimmune Therapeutics by 13.7% in the fourth quarter. Raymond James & Associates now owns 29,411 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,546 shares during the last quarter. Partnervest Advisory Services LLC purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter worth approximately $42,000. Polygon Management Ltd. raised its stake in shares of Adaptimmune Therapeutics by 71.5% in the fourth quarter. Polygon Management Ltd. now owns 857,311 shares of the biotechnology company’s stock worth $1,029,000 after purchasing an additional 357,311 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Adaptimmune Therapeutics by 5.2% in the third quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock worth $1,380,000 after purchasing an additional 45,249 shares during the last quarter. 65.03% of the stock is currently owned by institutional investors and hedge funds.

ADAP has been the topic of a number of research reports. ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. Finally, Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $5.86.

ADAP stock opened at $4.02 on Friday. The stock’s 50 day simple moving average is $3.15 and its 200 day simple moving average is $1.83. Adaptimmune Therapeutics has a fifty-two week low of $0.71 and a fifty-two week high of $6.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.93 and a current ratio of 3.93. The company has a market cap of $415.62 million, a P/E ratio of -2.89 and a beta of 1.47.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Article: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.